Madrigal Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Madrigal Pharmaceuticals, Inc. - overview
Established
2000
Location
-, PA, US
Primary Industry
Biotechnology
About
Based in Pennsylvania, US, and founded in 2000 by CMO Rebecca Taub, Madrigal Pharmaceuticals, Inc. operates as a biopharmaceutical company providing novel therapeutics for non-alcoholic steatohepatitis, a liver disease with high unmet medical need. As of 2024, the company is listed on Nasdaq with ticker MDGL. In March 2024, Madrigal Pharmaceuticals, Inc.
raised USD 195 million in a private placement, selling 750,000 shares at USD 260 apiece on the Nasdaq Global Select Market. In addition, Underwriters were granted a 30-day option to purchase up to an additional 346,153 shares. Madrigal Pharmaceuticals, Inc. provides a liver-directed thyroid hormone receptor (THR) β-selective agonist, designed to target the underlying causes of NASH.
The company offers oral medication by reducing liver fat (steatosis), inflammation, and fibrosis, which are key factors in the progression of NASH. The therapy is in Phase 3 clinical trials, for patients with compensated cirrhosis. In addition, the firm provides a solution to improve liver health and prevent the severe complications associated with advanced NASH.
Current Investors
Bay City Capital, Baker Brothers Advisors, Armistice Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.madrigalpharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.